About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-59.81%
Return on Equity-389.40%
Return on Assets-84.88%
Miscellaneous
EmployeesN/A
Outstanding Shares17,090,000
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its quarterly earnings data on Tuesday, March, 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.07. The biopharmaceutical company earned $6.32 million during the quarter, compared to the consensus estimate of $5.86 million. NovaBay Pharmaceuticals had a negative net margin of 59.81% and a negative return on equity of 389.40%. View NovaBay Pharmaceuticals' Earnings History.
What price target have analysts set for NBY?
4 equities research analysts have issued twelve-month price objectives for NovaBay Pharmaceuticals' stock. Their predictions range from $4.00 to $8.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $6.00 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include U.S. Geothermal (HTM), Asterias Biotherapeutics (AST), Orchids Paper Products (TIS), inTest (INTT), Matinas BioPharma (MTNB), Ur-energy (URG), Contango Oil & Gas (MCF), Unique Fabricating (UFAB), Transatlantic Petroleum (TAT), Bovie Medical (BVX), CPI Aerostructures (CVU), Vista Gold (VGZ), Globalscape (GSB), Acme United (ACU), UQM Technologies (UQM), McClatchy (MNI), eMagin (EMAN) and OncoCyte (OCX).
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the folowing people:
- Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)
- Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)
- Mr. John J. McGovern, CFO, Treasurer & Principal Accounting Officer
- Dr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)
- Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59)
Has NovaBay Pharmaceuticals been receiving favorable news coverage?
News articles about NBY stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovaBay Pharmaceuticals earned a news impact score of 0.19 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of NovaBay Pharmaceuticals?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovaBay Pharmaceuticals' stock price today?
One share of NBY stock can currently be purchased for approximately $3.3340.
How big of a company is NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals has a market capitalization of $52.51 million.
How can I contact NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.
MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Earnings History and Estimates Chart
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/20/2018 | Q4 2017 | ($0.05) | $0.02 | $5.86 million | $6.32 million | View | N/A |  |
| 11/14/2017 | Q3 | ($0.07) | ($0.16) | $4.69 million | $4.09 million | View | N/A | |
| 8/10/2017 | Q2 2017 | ($0.12) | ($0.1140) | $4.57 million | $4.12 million | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.14) | ($0.26) | $4.08 million | $3.70 million | View | N/A | |
| 3/23/2017 | Q4 2016 | ($0.12) | ($0.13) | $4.03 million | $4.08 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.16) | ($0.34) | $3.02 million | $3.40 million | View | N/A | |
| 8/11/2016 | Q216 | ($0.30) | ($0.36) | $1.76 million | $2.70 million | View | Listen | |
| 5/12/2016 | Q116 | ($0.68) | ($1.24) | $1.84 million | $1.70 million | View | Listen | |
| 3/3/2016 | Q415 | ($1.36) | ($1.26) | $1.43 million | $1.60 million | View | N/A | |
| 11/19/2015 | Q315 | ($0.07) | ($0.07) | $1.06 million | $1.20 million | View | Listen | |
| 8/13/2015 | Q215 | ($0.07) | ($0.07) | $610.00 million | $1.01 million | View | Listen | |
| 5/14/2015 | Q1 | ($0.06) | ($0.09) | | $0.54 million | View | N/A | |
| 3/26/2015 | Q414 | ($0.07) | ($0.09) | | $0.49 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.09) | ($0.08) | | $0.15 million | View | N/A | |
| 7/31/2014 | | ($0.09) | ($0.06) | | $0.12 million | View | N/A | |
| 5/1/2014 | Q114 | ($0.11) | ($0.08) | | $0.19 million | View | N/A | |
| 3/7/2014 | Q4 2013 | | $2.50 | | $0.37 million | View | N/A | |
| 11/12/2013 | Q3 | | ($0.10) | | $1.10 million | View | N/A | |
| 8/1/2013 | Q2 2013 | | ($2.75) | | $0.85 million | View | N/A | |
| 5/2/2013 | Q113 | ($0.07) | ($0.11) | $1.18 million | $0.96 million | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.09) | ($0.08) | $1.50 million | | View | N/A | |
| 8/9/2012 | Q2 2012 | ($2.00) | ($1.95) | | | View | N/A | |
| 5/3/2012 | Q1 2012 | ($1.75) | ($2.23) | | | View | N/A | |
| 3/27/2012 | Q4 2011 | | ($2.30) | | | View | N/A | |
| 11/7/2011 | Q3 2011 | ($1.75) | ($0.30) | | | View | N/A | |
| 8/10/2011 | Q2 2011 | ($2.00) | $0.45 | | | View | N/A | |
| 5/16/2011 | Q1 2011 | | ($2.00) | | | View | N/A | |
| 3/10/2011 | Q4 2010 | ($2.00) | $0.18 | | | View | N/A | |
| 11/12/2010 | Q3 2010 | ($1.75) | ($1.75) | | | View | N/A | |
| 8/12/2010 | Q2 2010 | ($1.75) | ($1.28) | | | View | N/A | |
| 5/12/2010 | Q1 2010 | ($2.00) | ($1.75) | | | View | N/A | |
| 3/30/2010 | Q4 2009 | ($0.50) | $3.58 | | | View | N/A | |
| 11/13/2009 | Q3 2009 | ($0.25) | ($0.13) | | | View | N/A | |
| 8/14/2009 | Q2 2009 | ($2.50) | ($0.33) | | | View | N/A | |
| 5/18/2009 | Q1 2009 | ($1.25) | ($0.38) | | | View | N/A | |
| 4/1/2009 | Q4 2008 | ($2.50) | ($1.75) | | | View | N/A | |
| 11/14/2008 | Q3 2008 | ($3.75) | ($1.73) | | | View | N/A | |
| 8/14/2008 | Q2 2008 | ($3.25) | ($2.83) | | | View | N/A | |
| 5/14/2008 | Q1 2008 | | ($3.15) | | | View | N/A | |
| 3/11/2008 | Q4 2007 | | ($2.13) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trading and Institutional Ownership History
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/25/2017 | Jacques Bonneau | Director | Buy | 25,000 | $0.22 | $5,500.00 | | |
| 10/18/2017 | Jacques Bonneau | Director | Buy | 50,000 | $0.16 | $8,000.00 | | |
| 9/8/2017 | Jean-Sébastien David | Director | Buy | 12,300 | $0.20 | $2,460.00 | | |
| 9/7/2017 | Jean-Sébastien David | Director | Buy | 15,000 | $0.20 | $3,000.00 | | |
| 9/6/2017 | Claude Dufresne | Director | Buy | 10,000 | $0.21 | $2,100.00 | | |
| 8/21/2017 | Claude Dufresne | Director | Buy | 10,000 | $0.13 | $1,300.00 | | |
| 6/26/2017 | Serge Savard | Director | Buy | 52,000 | $0.18 | $9,360.00 | | |
| 6/23/2017 | Serge Savard | Director | Buy | 10,000 | $0.17 | $1,700.00 | | |
| 6/21/2017 | Serge Savard | Director | Buy | 18,500 | $0.17 | $3,145.00 | | |
| 6/20/2017 | Serge Savard | Director | Buy | 101,000 | $0.17 | $17,170.00 | | |
| 6/19/2017 | Serge Savard | Director | Buy | 18,500 | $0.17 | $3,145.00 | | |
| 4/26/2017 | Claude Dufresne | Director | Buy | 2,000 | $0.76 | $1,520.00 | | |
| 3/6/2017 | Jean-Sébastien David | Director | Buy | 3,820 | $0.81 | $3,094.20 | | |
| 1/12/2017 | Claude Dufresne | Director | Sell | 21,000 | $0.77 | $16,170.00 | | |
| 8/20/2015 | Ramin Najafi | CEO | Buy | 12,000 | $0.47 | $5,640.00 | | |
| 3/3/2015 | Pharma (Singapore) Pte Pioneer | Major Shareholder | Buy | 2,590,000 | $0.60 | $1,554,000.00 | | |
| 3/3/2015 | Ramin Najafi | Chairman | Buy | 166,666 | $0.60 | $99,999.60 | | |
| 12/12/2014 | Ramin Najafi | Chairman | Buy | 50,000 | $0.65 | $32,500.00 | | |
| 12/12/2014 | Thomas J Paulson | CFO | Buy | 10,000 | $0.68 | $6,800.00 | | |
| 12/11/2014 | Ramin Najafi | Chairman | Buy | 20,000 | $0.60 | $12,000.00 | | |
| 12/9/2014 | Thomas J Paulson | CFO | Buy | 10,000 | $0.67 | $6,700.00 | | |
| 12/5/2014 | Ramin Najafi | Chairman | Buy | 25,000 | $0.65 | $16,250.00 | | |
| 12/2/2014 | Ramin Najafi | Chairman | Buy | 18,000 | $0.71 | $12,780.00 | | |
| 12/2/2014 | Tony D.S. Wicks | Director | Sell | 20,000 | $0.70 | $14,000.00 | | |
| 6/4/2014 | Mark M Sieczkarek | Director | Buy | 4,800 | $0.89 | $4,272.00 | | |
| 5/19/2014 | Mark M Sieczkarek | Director | Buy | 25,000 | $0.88 | $22,000.00 | | |
| 5/13/2014 | Pioneer Pharma Holdings China | Major Shareholder | Buy | 65,065 | $0.99 | $64,414.35 | | |
| 5/12/2014 | Pioneer Pharma Holdings China | Major Shareholder | Buy | 116,107 | $0.99 | $114,945.93 | | |
| 5/9/2014 | Pioneer Pharma Holdings China | Major Shareholder | Buy | 318,828 | $0.99 | $315,639.72 | | |
| 12/2/2013 | Pioneer Pharma Holdings China | Major Shareholder | Buy | 5,000,000 | $1.14 | $5,700,000.00 | | |
| 12/11/2012 | Xinzhou Li | Insider | Buy | 120,000 | $1.20 | $144,000.00 | | |
| 12/6/2012 | Ramin Najafi | Chairman | Buy | 20,000 | $1.24 | $24,800.00 | | |
| 12/6/2012 | Thomas J Paulson | CFO | Buy | 10,000 | $1.24 | $12,400.00 | | |
| 10/31/2012 | Area Pioneer Pharma Co. Naqu | Major Shareholder | Buy | 1,200,000 | $1.25 | $1,500,000.00 | | |
| 9/13/2012 | Xinzhou Li | Major Shareholder | Buy | 800,000 | $1.25 | $1,000,000.00 | | |
(Data available from 1/1/2013 forward)
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NovaBay Pharmaceuticals (NBY) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:45 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 1:54 AM |
| NovaBay Pharmaceuticals (NBY) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 27 at 7:27 PM |
 | Roth Capital Downgrades NovaBay Pharmaceuticals (NBY) to Neutral
www.streetinsider.com - March 26 at 4:10 PM |
| NovaBay Pharmaceuticals (NBY) Downgraded to "Hold" at Roth Capital
www.americanbankingnews.com - March 26 at 10:33 AM |
| HC Wainwright Analysts Give NovaBay Pharmaceuticals (NBY) a $6.00 Price Target
www.americanbankingnews.com - March 21 at 3:57 PM |
 | NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 20 at 4:10 PM |
| BRIEF-Jinzi Ham's Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiary's Capital
finance.yahoo.com - March 12 at 5:19 PM |
| NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 7 at 1:50 AM |
| NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
finance.yahoo.com - February 21 at 9:52 AM |
| NovaBay Pharmaceuticals (NBY) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 15 at 6:26 AM |
 | Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
seekingalpha.com - February 14 at 9:01 AM |
| NovaBay Pharmaceuticals Completes $6.0 Million Private Placement
finance.yahoo.com - February 12 at 8:57 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 1:48 AM |
| NovaBay Pharmaceuticals (NBY) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 12:06 PM |
| NovaBay Pharma (NBY) Enters Share Purchase Agreement for Sale of 1,700,000 Shares of Common Stock
www.streetinsider.com - February 6 at 4:33 PM |
| NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 2:04 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Short Interest Up 32.1% in December
www.americanbankingnews.com - January 10 at 6:06 PM |
| NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
finance.yahoo.com - January 8 at 8:04 AM |
 | NovaBay Pharmaceuticals Gets Stockholder Approval for Proposed $10.32 Mln Financing Deal
www.nasdaq.com - December 22 at 9:17 AM |
| NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
finance.yahoo.com - December 22 at 9:17 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 22 at 2:06 AM |
| NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
finance.yahoo.com - December 21 at 9:07 AM |
| ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:20 PM |
| NovaBay Pharma (NBY) Names Lewis Stuart CCO
www.streetinsider.com - December 6 at 5:39 PM |
| ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:18 PM |
| NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:09 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM |
| HC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target
www.americanbankingnews.com - November 19 at 5:38 PM |
| Laidlaw Trims NovaBay Pharmaceuticals, Inc. (NBY) Target Price to $8.00
www.americanbankingnews.com - November 19 at 11:14 AM |
| NovaBay Pharmaceuticals, Inc. (NBY) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - November 15 at 1:05 PM |
| NovaBay Pharmaceuticals, Inc. (NBY) Price Target Cut to $8.00
www.americanbankingnews.com - November 15 at 8:28 AM |
| NovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 15 at 6:40 AM |
| BRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder
finance.yahoo.com - November 15 at 6:40 AM |
| NovaBay Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 6:40 AM |
| NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:40 AM |
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Income Statement, Balance Sheet and Cash Flow Statement
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Stock Chart for Saturday, April, 21, 2018
Loading chart…
